← Back to Clinical Trials
Recruiting NCT03657745

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

Trial Parameters

Condition Alzheimer Disease
Sponsor Alzheimer's Light LLC
Study Type OBSERVATIONAL
Phase N/A
Enrollment 2,000
Sex ALL
Min Age 50 Years
Max Age N/A
Start Date 2018-01-01
Completion 2029-12-31
Interventions
Combination of 40Hz light and cognitive therapy (ALZLIFE)

Brief Summary

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.

Eligibility Criteria

Inclusion Criteria: * Alzheimer's disease * Cognitive Impairment Exclusion Criteria: * any previously noted epileptic seizures, including febrile seizures. * any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.

Related Trials